Global Industry Analysts, Inc., May 2008, Pages: 527
This report analyzes the worldwide markets for CNS Therapeutics in Millions of US$. The specific product Groups analyzed are Anti-Alzheimers, Anti-Parkinsons, Anti-Epilepsy, Pain Management
C4cast, Dec 2011, Pages: 7
The Economy Matters Report For Cns: The Economy's Impact On Cns's Price And Risk, Featuring The Powerful Economic Climate Rating.
ValuEngine, Inc., Feb 2012, Pages: 12
Advanced academic research that brings you superior investment strategies in an actionable format. The most comprehensive and useful report available. Our three models: Valuation Model, Forecast
GBI Research, Sep 2011, Pages: 97
status by geography, by sponsor company, and by year for all the major CNS indications. Furthermore, the report provides profiles of prevalence with forecast data up to 2017 for all the major CNS
Jain PharmaBiotech, Feb 2012, Pages: 345
therapy companies with products in development for CNS disorders are included. References contains over 400 publications that are cited in the report. The report is supplemented with 51 tables and 9 figures
John Wiley and Sons Ltd, Jan 2010, Pages: 324
CNS drugs as identified by the FDA in their report on the slowdown in the development new chemical entities across the disease spectrum.
Key Features:
- Discusses in detail the key stages of CNS
Bizacumen Inc., Nov 2009, Pages: 305
tendencies among adolescents.
These and other market data and trends are presented in "CNS Therapeutics: World Market Review" by BizAcumen, Inc. Our reports are designed to be most comprehensive in geographic
GBI Research, Dec 2009, Pages: 198
needs, drivers and barriers that impact the global CNS diseases therapeutics market. The report analyzes the markets for CNS disease therapeutics in the US, the top five countries in Europe (the UK
Business Insights, Jan 2007, Pages: 224
their success in the commercial market. This report will enable you to understand the research tactics of your competitors and develop winning strategies for future growth in the lucrative CNS market. The report
GBI Research, Nov 2011, Pages: 230
Accounted for Half the Market Value in 2010”, which provides insights into CNS disorder therapeutics market until 2017. The report is built using data and information sourced from proprietary databases
Select Biosciences Ltd, Jan 2010, Pages: 113
This is the latest and most up-to-date Market Report from Select Biosciences addressing the cellular therapy space. Select Biosciences’ industry coverage of the stem cells space is broad
Venture Planning Group, Sep 2011
This report provides industry executives with strategically significant competitor information and analysis of the leading players in the Global CNS Market.
The report provides a worldwide
Medpredict, July 2010, Pages: 134
This report summarizes the consensus findings from six US based anesthesiologists. This elite group identifies unmet needs in the treatment of acute and chronic pain, shares their current favorite
Business Insights, July 2002
With sales of up to $52bn in 2001, and a growth rate of over 10%, the CNS market represents the second largest therapeutic segment of the pharmaceutical market, and one of the fastest growing
